Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone

NCT01993641 is registered in ClinicalTrials.gov with Helsinn Healthcare SA as lead sponsor.

NCT NCT01993641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01993641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Lead sponsor
Helsinn Healthcare SA
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
June 30, 2016
Enrollment
45 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

mds, myelodysplastic syndrome